SynthesisBMC pulmonary medicine2025
New insights on Bronchial Artery Embolization (BAE) for hemoptysis: a systematic review.
Synthesis in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Prospective concordance of multidetector CT angiography and digital subtraction angiography in assessing bronchial artery morphology for hemoptysis embolization outcomes.The Libyan journal of medicine · 2026Article
- Transcatheter embolization of systemic artery-to-pulmonary artery shunts with n-butyl-2-cyanoacrylate for pediatric hemoptysis: a single-center retrospective study.BMC pediatrics · 2026Article
- The hemodynamic and clinical characteristics of recurrent hemoptysis in bronchiectasis patients after vascular intervention procedures.Journal of thoracic disease · 2026Article
- Distinct bacterial profiles according to structural lung disease in patients undergoing bronchial artery embolization for hemoptysis.Frontiers in medicine · 2026Article
- Deep learning-assisted 3D CT angiography for supply-vessel localization in inflammatory peripheral pulmonary artery pseudoaneurysms.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBronchial Artery Embolization (BAE) is a well-established, non-surgical treatment for hemoptysis. This systematic review aims to update the current literature on BAE for hemoptysis, focusing on indications, techniques, complications, clinical outcomes, and recurrence rates.
methodsWe conducted a systematic review of studies published between May 2016 and July 2025. Eligible studies included patients who underwent BAE for hemoptysis, with more than 50 participants and detailed reporting on indications, techniques, complications, outcomes, and recurrence rates.
resultsThirty-two studies were included. The leading causes of hemoptysis were bronchiectasis (27%), post-tubercular sequelae (17.7%), tuberculosis (15.6%), and lung malignancies (15%). Technical success rates ranged from 64% to 100%, with a median technical success of 98.1% (IQR 91.2-100%). Immediate clinical success ranged from 77.3% to 100%, with a median of 94.0% (IQR 89.8-97.9%). Recurrence rates ranged from 5.2% to 55%. The pooled median recurrence rates were 10.6% (IQR 6.9-19.1%) at 6 months, 23.0% (IQR 19.7-28.3%) at 1 year, 29.8% (IQR 25.2-36.6%) at 2 years, and 34.6% (IQR 34.0-37.3%) at 4-5 years. Complications were predominantly minor (median 10.6%) while major complications occurred in 0-4.8% of cases.
conclusionBAE remains a highly effective and minimally invasive treatment for hemoptysis, with high success and low complication rates. Recurrence can be reduced through optimized imaging, CTA-guided planning, and tailored embolization techniques. A multidisciplinary, patient-centered strategy incorporating radiologic expertise and emerging AI tools may further enhance outcomes and prevent recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.